Episode Details

Back to Episodes

Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections

Episode 188 Published 3 years, 6 months ago
Description

CAR-T cell therapy represents a major breakthrough in the treatment of hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia (ALL). However, there are several toxicities associated with these agents, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections.

In this podcast, you will hear from experts Eleni Gavriilaki, MD, PhD, G. Papanikolaou Hospital, Thessaloniki, Greece, Kevin McNerney, MD, MSc, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, and Andriyana Bankova, MD, University Hospital Zurich, Zurich, Switzerland, who share some insights into the treatment and management of these common toxicities.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us